scholarly journals Homotypic Cell Membrane-Cloaked Biomimetic Nanocarrier for the Targeted Chemotherapy of Hepatocellular Carcinoma

Theranostics ◽  
2019 ◽  
Vol 9 (20) ◽  
pp. 5828-5838 ◽  
Author(s):  
Xiaojun Liu ◽  
Yingxue Sun ◽  
Shushen Xu ◽  
Xiaonan Gao ◽  
Fanpeng Kong ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Membrane ◽  
Targeted Chemotherapy

scholarly journals Cancer cell membrane-camouflaged MOF nanoparticles for a potent dihydroartemisinin-based hepatocellular carcinoma therapy

RSC Advances ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 7194-7205 ◽  
Author(s):  
Yusha Xiao ◽  
Wei Huang ◽  
Daoming Zhu ◽  
Quanxiong Wang ◽  
Baiyang Chen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Membrane ◽  
Cancer Treatment ◽  
Cancer Cell ◽  
New Drugs

Developing new drugs for cancer treatment remains a challenging task.

Detection of anti-liver cell membrane antibody using a human hepatocellular carcinoma cell line

Hepatology ◽  
1989 ◽  
Vol 9 (2) ◽  
pp. 210-214 ◽  
Author(s):  
Ava Lobo-Yeo ◽  
Claire McSorley ◽  
Barbara M. McFarlane ◽  
Giorgina Mieli-Vergani ◽  
Alex P. Mowat ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Membrane ◽  
Cell Line ◽  
Liver Cell ◽  
Carcinoma Cell ◽  
Human Hepatocellular Carcinoma ◽  
Carcinoma Cell Line ◽  
Hepatocellular Carcinoma Cell Line ◽  
Human Hepatocellular Carcinoma Cell ◽  
Hepatocellular Carcinoma Cell

scholarly journals AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers

2021 ◽  
Vol 9 ◽  
Author(s):  
Bo Lin ◽  
Xu Dong ◽  
Qiujiao Wang ◽  
Wei Li ◽  
Mingyue Zhu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Delivery ◽  
Drug Resistance ◽  
Cancer Cells ◽  
Immune Cells ◽  
Targeted Chemotherapy ◽  
Patients With Cancer ◽  
Important Target ◽  
Intracellular Proteins ◽  
New Strategy

Alpha fetoprotein (AFP) plays a key role in stimulating the growth, metastasis and drug resistance of hepatocellular carcinoma (HCC). AFP is an important target molecule in the treatment of HCC. The application of AFP-derived peptides, AFP fragments and recombinant AFP (AFP-inhibiting fragments, AIFs) to inhibit the binding of AFP to intracellular proteins or its receptors is the basis of a new strategy for the treatment of HCC and other cancers. In addition, AIFs can be combined with drugs and delivery agents to target treatments to cancer. AIFs conjugated to anticancer drugs not only destroy cancer cells with these drugs but also activate immune cells to kill cancer cells. Furthermore, AIF delivery of drugs relieves immunosuppression and enhances chemotherapy effects. The synergism of immunotherapy and targeted chemotherapy is expected to play an important role in enhancing the treatment effect of patients with cancer. AIF delivery of drugs will be an available strategy for the targeted treatment of cancer in the future.

scholarly journals Preclinical verification of the efficacy by targeting peptide-linked liposomal nanoparticles for hepatocellular carcinoma therapy

2019 ◽  
Vol 6 ◽  
pp. 184954351988076
Author(s):  
Cheng-Der Wu ◽  
Jen-Chieh Lee ◽  
Hang-Chung Wu ◽  
Chung-Wei Lee ◽  
Chih-Feng Lin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Membrane ◽  
Adverse Events ◽  
Liposomal Doxorubicin ◽  
Hepatoma Cell ◽  
Immunodeficient Mice ◽  
Nonobese Diabetic ◽  
Control Peptide ◽  
Liposomal Nanoparticles ◽  
Targeting Peptide

The purpose of this study was to investigate the efficacy of targeting peptides chemotherapy to overcome adverse event in the conventional chemotherapy for human hepatocellular carcinoma. Previously we reported several cancer-targeting peptides that bind specifically to cancer cells and their vascular endothelia: L-peptide (anti-cancer cell membrane), RLLDTNRPLLPY; SP-94-peptide (anti-hepatoma cell membrane), SFSHHTPILP; PC5-52-peptide (anti-tumor endothelia), SVSVGMKPSPRP; and control peptide, RLLDTNRGGGGG. In this study, these peptides were linked to liposomal iron oxide nanoparticles to localize the targeted tumor cells and endothelia, and to dextran-coated liposomal doxorubicin (L-D) to treat nonobese diabetic severe combined immunodeficient mice bearing hepatoma xenografts. Our results showed that L-peptide-linked liposomal doxorubicin could inhibit tumor growth with very mild adverse events. Use of the control peptide led to a decrease in the xenograft size but also led to marked apoptotic change in the visceral organ. In conclusion, L-peptide-linked liposomal doxorubicin, SP-94-peptide, and PC5-52-peptide can be used for the treatment of hepatoma xenografts in nonobese diabetic severe combined immunodeficient mice with minimal adverse events.

scholarly journals High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma

2019 ◽  
Vol 9 ◽  
Author(s):  
Yilan Ma ◽  
Mingjiong Zhang ◽  
Jiayan Wang ◽  
Xiaochen Huang ◽  
Xingwang Kuai ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Targeted Chemotherapy ◽  
High Affinity

scholarly journals A Human Anti-c-Met Fab Fragment Conjugated with Doxorubicin as Targeted Chemotherapy for Hepatocellular Carcinoma

PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
pp. e63093 ◽  
Author(s):  
Ximin Chen ◽  
Guipeng Ding ◽  
Qihe Gao ◽  
Jian Sun ◽  
Qianqian Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Targeted Chemotherapy ◽  
Fab Fragment
Sign in / Sign up

Export Citation Format

Share Document